Ultragenyx Announces Closing of Initial Public Offering and Exercise of Underwriters' Option to

NOVATO, Calif., Feb. 5, 2014 (GLOBE NEWSWIRE) — Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development of